A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

NCT05955105 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Cervical Cancer
Endometrial Cancer
Triple Negative Breast Cancer
Ovarian Cancer
Soft Tissue Sarcoma
Melanoma
Nasopharyngeal Carcinoma
Non Small Cell Lung Cancer
Classic Hodgkin Lymphoma

Interventions

DRUG: ILB-2109
DRUG: Toripalimab

Sponsor

Innolake Biopharm